|
|
|
Insider
Information: |
Edelman Joseph |
Relationship: |
Former 10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
42 |
|
Direct
Shares |
630,171 |
|
Indirect Shares
|
332,164,708 |
|
|
Direct
Value |
$1,292,299 |
|
|
Indirect Value
|
$2,768,839,815 |
|
|
Total
Shares |
332,794,879 |
|
|
Total
Value |
$2,770,132,114 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
79
|
21
|
Stock
price went up :
|
50
|
11
|
Stock
price went down : |
29
|
10
|
|
|
|
Gain/Loss Ratio : |
1.7
|
1.1
|
Percentage
Gain/Loss : |
11.7%
|
182.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Penwest Pharmaceuticals Co |
PPCO |
10% Owner |
2008-06-23 |
0 |
2008-06-23 |
6,387,546 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
10% Owner |
|
0 |
2011-11-02 |
0 |
Premium* |
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
10% Owner |
2012-11-01 |
133,133 |
2012-11-29 |
2,595,293 |
Premium* |
|
Acelrx Pharmaceuticals Inc |
ACRX |
10% Owner |
|
0 |
2017-06-19 |
4,533,728 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
10% Owner |
|
0 |
2018-10-03 |
20,724,424 |
Premium* |
|
VBI Vaccines Inc |
VBIV |
10% Owner |
|
0 |
2014-07-25 |
2,610,356 |
Premium* |
|
Aldeyra Therapeutics, Inc. |
ALDX |
10% Owner |
|
0 |
2024-04-05 |
9,275,851 |
Premium* |
|
Aravive Inc |
ARAV |
10% Owner |
|
0 |
2017-09-22 |
2,099,563 |
Premium* |
|
Kadmon Holdings, Llc |
KDMN |
10% Owner |
|
0 |
2019-11-18 |
14,636,334 |
Premium* |
|
Zogenix, Inc. |
ZGNX |
10% Owner |
2017-09-29 |
0 |
2018-08-10 |
4,070,357 |
Premium* |
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-12-19 |
0 |
2017-12-19 |
4,889,066 |
Premium* |
|
Corium International, Inc. |
CORI |
10% Owner |
2018-01-16 |
0 |
2018-10-12 |
2,724,686 |
Premium* |
|
Albireo Pharma Inc |
ALBO |
10% Owner |
2018-01-25 |
0 |
2022-10-13 |
1,939,723 |
Premium* |
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2024-01-11 |
6,906,646 |
Premium* |
|
La Jolla Pharmaceutical Co |
LJPC |
10% Owner |
2018-02-13 |
0 |
2019-01-08 |
2,253,376 |
Premium* |
|
Motus Gi Holdings Inc |
MOTS |
10% Owner |
2018-02-16 |
0 |
2021-01-22 |
2,660,542 |
Premium* |
|
Quotient Ltd |
QTNTQ |
10% Owner |
2018-05-22 |
0 |
2022-10-31 |
7,945,211 |
Premium* |
|
Dova Pharmaceuticals, Inc. |
DOVA |
10% Owner |
2018-06-04 |
0 |
2019-11-12 |
0 |
Premium* |
|
Meiragtx Holdings Plc |
MGTX |
10% Owner |
2018-06-08 |
0 |
2023-05-05 |
11,281,103 |
Premium* |
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
10% Owner |
2018-07-20 |
0 |
2022-04-18 |
5,321,032 |
Premium* |
|
Agile Therapeutics Inc |
AGRX |
10% Owner |
2018-07-26 |
0 |
2021-10-13 |
21,654,485 |
Premium* |
|
Verrica Pharmaceuticals Inc. |
VRCA |
10% Owner |
2018-06-19 |
0 |
2023-12-29 |
7,099,182 |
Premium* |
|
Athenex, Inc. |
ATNX |
10% Owner |
2019-05-06 |
0 |
2020-09-14 |
13,532,467 |
Premium* |
|
ADMA Biologics Inc |
ADMA |
10% Owner |
2019-05-21 |
0 |
2021-09-30 |
13,262,375 |
Premium* |
|
Foamix Pharmaceuticals Ltd |
FOMX |
10% Owner |
|
0 |
2019-07-29 |
11,203,881 |
Premium* |
|
Lyra Therapeutics, Inc. |
LYRA |
Director, 10% Owner |
2020-05-05 |
0 |
2023-05-31 |
12,757,563 |
Premium* |
|
VYNE Therapeutics Inc |
VYNE |
10% Owner |
2020-06-09 |
0 |
2021-08-16 |
4,935,057 |
Premium* |
|
Leap Therapeutics, Inc. |
LPTX |
10% Owner |
2020-06-22 |
0 |
2020-06-22 |
8,476,496 |
Premium* |
|
Athira Pharma, Inc. |
ATHA |
Director, 10% Owner |
|
0 |
2023-12-29 |
5,402,964 |
Premium* |
|
Cerevel Therapeutics Holdings, I... |
CERE |
Director |
2020-10-20 |
0 |
2024-02-20 |
10,794,876 |
Premium* |
|
Scynexis Inc |
SCYX |
10% Owner |
2021-01-20 |
0 |
2021-01-22 |
1,800,000 |
Premium* |
|
Landos Biopharma, Inc. |
LABP |
Director, 10% Owner |
|
0 |
2021-02-09 |
17,960,839 |
Premium* |
|
Astria Therapeutics, Inc |
ATXS |
Director |
|
0 |
2024-02-01 |
6,485,420 |
Premium* |
|
Prometheus Biosciences, Inc. |
RXDX |
10% Owner |
2021-03-16 |
0 |
2021-03-16 |
3,314,032 |
Premium* |
|
Rain Therapeutics Inc. |
RAIN |
10% Owner |
2021-04-27 |
0 |
2021-10-12 |
2,487,019 |
Premium* |
|
Nautilus Biotechnology, Inc |
NAUT |
10% Owner |
2021-05-24 |
497,038 |
2021-12-08 |
9,111,151 |
Premium* |
|
Isoplexis Corp |
ISO |
10% Owner |
2021-10-12 |
0 |
2021-10-12 |
3,554,587 |
Premium* |
|
Lianbio |
LIAN |
Director, 10% Owner |
|
0 |
2024-02-15 |
57,575,533 |
Premium* |
|
Acrivon Therapeutics, Inc. |
ACRV |
10% Owner |
|
0 |
2024-04-11 |
5,360,858 |
Premium* |
|
Chembio Diagnostics Inc |
CEMI |
Former 10% Owner |
2023-04-04 |
0 |
2023-04-27 |
0 |
Premium* |
|
Soleno Therapeutics Inc |
SLNO |
10% Owner |
|
0 |
2023-06-06 |
2,207,753 |
Premium* |
|
Cargo Therapeutics, Inc. |
CRGX |
Former 10% Owner |
2023-11-14 |
0 |
2023-11-14 |
333,333 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
304 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 13
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
FOLD |
Amicus Therapeutics Inc |
10% Owner |
|
2018-09-21 |
4 |
B |
$12.53 |
$626,500 |
I/I |
50,000 |
20,674,424 |
1.5 |
- |
|
FOLD |
Amicus Therapeutics Inc |
10% Owner |
|
2018-09-24 |
4 |
B |
$12.45 |
$249,000 |
I/I |
20,000 |
20,694,424 |
1.5 |
- |
|
FOLD |
Amicus Therapeutics Inc |
10% Owner |
|
2018-10-03 |
4 |
B |
$12.69 |
$380,700 |
I/I |
30,000 |
20,724,424 |
1.5 |
- |
|
ARAV |
Aravive Inc |
10% Owner |
|
2016-09-28 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
3,871,286 |
|
- |
|
ARAV |
Aravive Inc |
10% Owner |
|
2016-09-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,797,419 |
|
- |
|
ARAV |
Aravive Inc |
10% Owner |
|
2017-09-21 |
4 |
S |
$3.56 |
$1,731,802 |
I/I |
(480,000) |
3,749,563 |
0 |
- |
|
ARAV |
Aravive Inc |
10% Owner |
|
2017-09-22 |
4 |
S |
$3.03 |
$5,281,750 |
I/I |
(1,650,000) |
2,099,563 |
0 |
- |
|
ATXS |
Astria Therapeutics, Inc |
Director |
|
2021-01-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,476,924 |
|
- |
|
ATXS |
Astria Therapeutics, Inc |
Director |
|
2022-12-19 |
4 |
B |
$11.01 |
$9,999,998 |
I/I |
908,265 |
1,038,309 |
2.1 |
% |
|
ATXS |
Astria Therapeutics, Inc |
Director |
|
2023-10-16 |
4 |
B |
$6.51 |
$6,999,997 |
I/I |
1,074,608 |
1,611,699 |
2.1 |
% |
|
ATXS |
Astria Therapeutics, Inc |
Director |
|
2023-12-21 |
4 |
B |
$6.20 |
$4,588,000 |
I/I |
740,000 |
2,392,371 |
2.1 |
% |
|
ATXS |
Astria Therapeutics, Inc |
Director |
|
2024-02-01 |
4 |
B |
$12.09 |
$29,999,522 |
I/I |
2,481,350 |
4,873,721 |
2.1 |
% |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-05-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,096,022 |
|
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-05-06 |
4 |
B |
$12.08 |
$1,271,148 |
I/I |
100,000 |
9,196,022 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-06-13 |
4 |
B |
$17.05 |
$1,290,856 |
I/I |
75,710 |
9,271,732 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-06-14 |
4 |
B |
$17.69 |
$5,736,690 |
I/I |
324,290 |
9,596,022 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-06-17 |
4 |
B |
$17.94 |
$2,332,200 |
I/I |
130,000 |
9,726,022 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-06-18 |
4 |
B |
$17.73 |
$899,656 |
I/I |
50,742 |
9,776,764 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-06-21 |
4 |
B |
$17.85 |
$411,853 |
I/I |
23,073 |
9,799,837 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-06-24 |
4 |
B |
$17.90 |
$372,069 |
I/I |
20,786 |
9,820,623 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-06-25 |
4 |
B |
$17.89 |
$26,746 |
I/I |
1,495 |
9,822,118 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-08-07 |
4 |
B |
$13.12 |
$10,576,251 |
I/I |
733,127 |
10,555,245 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-08-08 |
4 |
B |
$15.76 |
$472,800 |
I/I |
30,000 |
10,585,245 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-08-15 |
4 |
B |
$15.00 |
$450,000 |
I/I |
30,000 |
10,615,245 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-08-16 |
4 |
B |
$14.96 |
$299,200 |
I/I |
20,000 |
10,635,245 |
1.5 |
- |
|
304 Records found
|
|
Page 4 of 13 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|